TY - JOUR
T1 - Signifiant excess of early deaths after prehospital ticagrelor
T2 - The ATLANTIC trial challenge
AU - Serebruany, Victor
AU - Cherepanov, Vasily
AU - Dukhanin, Alexander
PY - 2015
Y1 - 2015
N2 - The recently published Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation Myocardial Infarction to Open the Coronary Artery (ATLANTIC) trial concluded that prehospital administration of ticagrelor in patients with acute STEMI appeared to be safe but did not improve pre-PCI coronary reperfusion. The ATLANTIC data fully support the PLATO Angiographic Substudy denying early benefit of ticagrelor, and correspond well with lack of immediate clinical benefit including the early PCI “death paradox” in PLATO-USA patients. Finally, there were significantly (p=0.043) more deaths in early ticagrelor ATLANTIC arm (odds ratio 3.18 (1.02–9.90) challenging stent thrombosis reduction. Indeed, ATLANTIC represents an important step for our better understanding of ticagrelor, although the confirmation of the PLATO mortality wonder in an adequately powered PEGASUS (TIMI-54) to be reported in 2015 will be vital for ticagrelor future.
AB - The recently published Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation Myocardial Infarction to Open the Coronary Artery (ATLANTIC) trial concluded that prehospital administration of ticagrelor in patients with acute STEMI appeared to be safe but did not improve pre-PCI coronary reperfusion. The ATLANTIC data fully support the PLATO Angiographic Substudy denying early benefit of ticagrelor, and correspond well with lack of immediate clinical benefit including the early PCI “death paradox” in PLATO-USA patients. Finally, there were significantly (p=0.043) more deaths in early ticagrelor ATLANTIC arm (odds ratio 3.18 (1.02–9.90) challenging stent thrombosis reduction. Indeed, ATLANTIC represents an important step for our better understanding of ticagrelor, although the confirmation of the PLATO mortality wonder in an adequately powered PEGASUS (TIMI-54) to be reported in 2015 will be vital for ticagrelor future.
UR - http://www.scopus.com/inward/record.url?scp=84934783769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934783769&partnerID=8YFLogxK
U2 - 10.1160/TH14-11-0936
DO - 10.1160/TH14-11-0936
M3 - Article
C2 - 25947272
AN - SCOPUS:84934783769
SN - 0340-6245
VL - 114
SP - 7
EP - 8
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 1
ER -